SERA reported test volume increased approximately fivefold from the first quarter of 2026, while Illinois and Florida Medicaid coverage supports nearly 7 million covered lives and approximately 140,000 annual births. Operating expenses fell 11% sequentially; cash reached $72.8 million.
SERA · Sera Prognostics, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $1.89
- Open
- $1.84
- Day range
- $1.80–1.94
- 52-week closing range
- $1.59–3.69
- Average volume, 30 days
- 34K
- Short interest
- 220K · 0.6% of shares · 9.1 days
- Short volume, last session
- 59%
- Last earnings
- Nov 4, 2026
- Latest filing
- 10-Q · Nov 4
- Price history
- Jul 2021 to Nov 2026
Up next
Latest documents
Sera Prognostics said nine-month net loss increased to $25.6 million from $24.0 million, while cash, cash equivalents and available-for-sale securities totaled $72.8 million; PreTRM gained Florida and Illinois Medicaid coverage, and expected cash funding extends into 2029.
Sera Prognostics reported third-quarter PreTRM test volume up 54% sequentially and revenue of $42,000, up 163% year over year. Florida Medicaid coverage expanded covered lives to approximately 7 million patients.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 4, 2026TL;DR. Commercial momentum accelerated: test volume rose 54% sequentially, ordering providers increased 34%, revenue rose 163% year over year, and Florida expanded Medicaid coverage. However, lower ASPs hurt revenue, the company remains loss-making and cash-consuming, physician adoption can take 12 to 18 months, and additional capital may be needed.
- + Florida and Illinois Medicaid coverage supports approximately 7 million covered lives and 140,000 annual births.
- + PreTRM test volume increased 54% sequentially and almost five-fold from the first quarter of 2026.
- + Ordering healthcare providers increased 34% sequentially and approximately three-fold from the first quarter of 2026.
- + Total PreTRM test revenue increased 163% year over year.
- + PRIME subgroup analysis showed PreTRM-guided care reduced NICU admissions among first-time mothers by 22%.
- + The company launched a fourth payer partnership program and discussed a large multi-state payer pilot planned for fiscal 2027.
- − Lower average selling prices negatively affected revenue because of a higher mix of low or non-reimbursed tests.
- − The company reported a third-quarter net loss.
- − Third-quarter cash burn from operations was $7.3 million.
- − Nine-month net cash used in operating activities was negative.
- − Physician adoption generally takes 12 to 18 months, delaying meaningful utilization of expanded ordering.
- − Net losses, cash generation, and the potential need to raise more capital are among the stated risks.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| cash, cash equivalents and available-for-sale securities | $80.3M | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SERA
this stock
Sera Prognostics, Inc.
|
$75.16M | -35.9% | +5.2% | — | 0.6% |
|
ABT
Abbott Laboratories
|
$179.90B | -17.1% | +5.7% | 38.8 | 1.1% |
|
MDT
Medtronic plc
|
$128.69B | +4.7% | +8.4% | 24.8 | 1.8% |
|
SYK
Stryker Corp
|
$119.19B | -10.9% | +11.2% | 33.3 | 1.7% |
|
BSX
Boston Scientific Corp
|
$62.31B | -54.9% | +12.5% | 18.2 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 4, 2026
- This year
- 19
Sera Prognostics said nine-month net loss increased to $25.6 million from $24.0 million, while cash, cash equivalents and available-for-sale securities totaled $72.8 million; PreTRM gained Florida and Illinois Medicaid coverage, and expected cash funding extends into 2029.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SERA | -4.6% | -7.4% | -13.7% | -7.4% | -35.9% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | +0.9% | -1.1% | -8.1% | -2.1% | -40.9% |